Lataa...
Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
BACKGROUND: Hypomethylating agents (HMA) are considered the first-line therapy for high-risk myelodysplastic syndromes (MDS). However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of reduced-dose azacitidine (AZA) vs. decitabine (DAC)...
Tallennettuna:
| Julkaisussa: | Med Sci Monit |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
International Scientific Literature, Inc.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7856837/ https://ncbi.nlm.nih.gov/pubmed/33514682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.928454 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|